These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36335201)

  • 1. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
    Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
    Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
    Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
    Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
    Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
    Kato Y; Kaneko MK
    Biochem Biophys Res Commun; 2013 Apr; 433(4):374-8. PubMed ID: 23524262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.
    Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA
    Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation-Based Characterization of a New
    Burgermeister S; Stoykova S; Krebs FS; Zoete V; Mbefo M; Egervari K; Reinhard A; Bisig B; Hewer E
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
    Raynaud S; Carbuccia N; Colin C; Adélaïde J; Mozziconacci MJ; Metellus P; Chinot O; Birnbaum D; Chaffanet M; Figarella-Branger D
    Oncol Lett; 2010 Sep; 1(5):883-884. PubMed ID: 22966399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
    Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
    Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
    Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
    Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
    Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
    Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
    Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
    Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
    Luo LQ; Peng ZY; Liu X; Yu WZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
    Kawakami S; Ochiai K; Kato Y; Michishita M; Hirama H; Obara R; Azakami D; Watanabe M; Omi T
    J Vet Med Sci; 2018 Jan; 80(1):85-91. PubMed ID: 29162772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
    Lee WY; Chen KC; Chen HY; Chen CY
    Biomed Res Int; 2014; 2014():364625. PubMed ID: 24995286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.